Medicortex Finland Oyj

Medicortex Finland Plc appointing new members for the Board of Directors


Medicortex Finland Plc, a biotechnology company located in Turku, Finland, with a proprietary biomarker technology for detection of traumatic brain injury (TBI), announces appointment of Nils Grönberg and Ville Ranta-Panula (MSc, MBA) as new members in company’s Board of Directors. Grönberg and Ranta-Panula supplement the team of scientists and clinicians with their diverse expertise in business development and management, among other skills.

Medicortex is an innovative clinical stage biotechnology company focusing on development of diagnostics and therapy for brain injuries. Company’s short-term focus is to complete development of a rapid urine test, company’s lead product ProbTBITM kit for detection of biomarkers of mild traumatic brain injury, followed by prototype production and clinical evaluation. Mr. Grönberg and Mr. Ranta-Panula will be part of the enterprise to move the company forward to bring its breakthrough products to the clinics to address a significant unmet medical need.

Mr. Grönberg has over 30 years of experience in leadership. He has held executive positions in several bigger and smaller foundations and companies in Finland. In addition to leadership, Grönberg has expertise in sales management, investing, and fundraising.

Mr. Ranta-Panula has MBA education and M.Sc. degree in Drug Development from University of Turku and his current position is Chief Commercial Officer at CRST Oy. Ranta-Panula is an experienced and globally networked drug and business development professional. He holds a Certified Board Member certificate and is a board member of Turun Hallituspartnerit ry, an association of Board Professionals. Ranta-Panula has expertise in budgeting, business strategy, clinical trials, and sales.

“Medicortex is honoured to have two experienced business professionals to join the Board of Directors. We believe that we have assembled a multiskilled accountable team for the company", says Dr. Adrian Harel, CEO of Medicortex. “The broad potential of our TBI technology pipeline combined with the supplemented outstanding team of professionals marks a major step forward in advancing Medicortex to the leading technology company in the field of noninvasive testing of head injury and beyond”, Dr. Harel adds. 

Mrs. Anna Tenstam and Dr. Adrian Harel were re-elected in the Board of Directors in the Annual General Meeting of the company.

Forward-looking statements

Certain statements in this communication are forward-looking statements. They are based on the views of the company’s management, as well as the understanding and assumptions of the company’s management based on the information available at present, and due to this, they may be forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors, which may result in that the company’s actual future results, operations, achievements and performance of the sector may differ significantly from the expectations casted in these statements. Forward-looking statements are not a guarantee of the company’s operational or financial performance in the future.



Adrian Harel, CEO
Tel:+358 400 488 817


About Medicortex Finland Oyj

Medicortex Finland Oyj is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is on developing biomarker diagnostics to detect brain injury easily. The company has technology to capture biomarkers from urine and saliva and capability to develop an affordable diagnostic tool to detect biomarkers. Company's second goal is to develop new compounds to serve as drug candidates to halt progression of brain injury and reduce the secondary degeneration. Medicortex was founded by an experienced Neurobiologist Adrian Harel (PhD, MBA) and the company is based in Turku, Finland.

Subscribe to releases from Medicortex Finland Oyj

Subscribe to all the latest releases from Medicortex Finland Oyj by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Medicortex Finland Oyj

Turun kaupunki myönsi Medicortexille TKI-setelin15.6.2023 13:21:40 EEST | Tiedote

Medicortex Finland Oyj, turkulainen aivovammojen diagnostiikkaan ja lääkekehitykseen erikoistunut yritys, on saanut 5000 euron arvoisen TKI (tutkimus, kehitys- ja innovaatio-osaaminen) -setelin Turun kaupungilta. Seteli käytetään Turun yliopiston kanssa yhteistyössä tehtävän tutkimushankkeen edistämiseen. Hankkeen tarkoituksena on tutkia sähkömagneettisen säteilyn vaikutusta keskushermostoon koe-eläinmallissa.

Medicortexin kevään 2023 osakeanti päättynyt – yhtiö kiitollinen yleisön mielenkiinnosta30.5.2023 10:45:00 EEST | Tiedote

Medicortex Finland Oyj, tapaturmaisen aivovamman diagnostiikkaa ja hoitoa kehittävä turkulainen bioteknologiayhtiö, on saanut päätökseen osakeantikampanjan toisen kierroksen. Kampanjan aikana, joka sijoittui 2023 vuoden ensimmäiselle puolikkaalle, yritys keräsi yli 110 000 euroa. Saadut varat käytetään uusien hankkeiden aktivoimiseen yhtiön ensisijaisen tuotekehitysprojektin rinnalla.

Medicortex concluding the fundraising round of spring 2023 – company grateful for the public interest30.5.2023 10:45:00 EEST | Press release

Medicortex Finland Plc, a biopharmaceutical company focusing on the development of diagnostics for mild traumatic brain injury (TBI), and drug development for the same indication, announces completion of a second round of the fundraising campaign. In the two funding rounds that took place in the first half of 2023, the company has raised more than 110,000 euros. The funds raised will be used to activate research projects in parallel to company’s main product development program.

HiddenA line styled icon from Orion Icon Library.Eye